Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Oncogene ; 37(5): 663-672, 2018 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-29035389

RESUMO

E-cadherin and ß-catenin are key proteins that are essential in the formation of the epithelial cell layer in the colon but their regulatory pathways that are disrupted in cancer metastasis are not completely understood. Mutated in colorectal cancer (MCC) is a tumour suppressor gene that is silenced by promoter methylation in colorectal cancer and particularly in patients with increased lymph node metastasis. Here, we show that MCC methylation is found in 45% of colon and 24% of rectal cancers and is associated with proximal colon, poorly differentiated, circumferential and mucinous tumours as well as increasing T stage and larger tumour size. Knockdown of MCC in HCT116 colon cancer cells caused a reduction in E-cadherin protein level, which is a hallmark of epithelial-mesenchymal transition in cancer, and consequently diminished the E-cadherin/ß-catenin complex. MCC knockdown disrupted cell-cell adhesive strength and integrity in the dispase and transepithelial electrical resistance assays, enhanced hepatocyte growth factor-induced cell scatter and increased tumour cell invasiveness in an organotypic assay. The Src/Abl inhibitor dasatinib, a candidate anti-invasive drug, abrogated the invasive properties induced by MCC deficiency. Mechanistically, we establish that MCC interacts with the E-cadherin/ß-catenin complex. These data provide a significant advance in the current understanding of cell-cell adhesion in colon cancer cells.


Assuntos
Caderinas/metabolismo , Adesão Celular/genética , Neoplasias Colorretais/patologia , Proteínas Supressoras de Tumor/deficiência , beta Catenina/metabolismo , Antígenos CD , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Adesão Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Estudos de Coortes , Colo/citologia , Colo/patologia , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/genética , Neoplasias Colorretais/mortalidade , Metilação de DNA/genética , Dasatinibe/farmacologia , Dasatinibe/uso terapêutico , Transição Epitelial-Mesenquimal/genética , Regulação Neoplásica da Expressão Gênica , Técnicas de Silenciamento de Genes , Células HCT116 , Humanos , Metástase Linfática , Invasividade Neoplásica/genética , Estadiamento de Neoplasias , Prognóstico , Regiões Promotoras Genéticas/genética , Ligação Proteica/genética , Proteínas Supressoras de Tumor/genética
2.
Oncogene ; 35(22): 2834-41, 2016 06 02.
Artigo em Inglês | MEDLINE | ID: mdl-26455321

RESUMO

The loss of ß-catenin inhibitory components is a well-established mechanism of carcinogenesis but ß-catenin hyperactivity can also be enhanced through its coactivators. Here we first interrogated a highly validated genomic screen and the largest repository of cancer genomics data and identified JRK as a potential new oncogene and therapeutic target of the ß-catenin pathway. We proceeded to validate the oncogenic role of JRK in colon cancer cells and primary tumors. Consistent with a ß-catenin activator function, depletion of JRK in several cancer cell lines repressed ß-catenin transcriptional activity and reduced cell proliferation. Importantly, JRK expression was aberrantly elevated in 21% of colorectal cancers, 15% of breast and ovarian cancers and was associated with increased expression of ß-catenin target genes and increased cell proliferation. This study shows that JRK is required for ß-catenin hyperactivity regardless of the adenomatous polyposis coli/ß-catenin mutation status and targeting JRK presents new opportunities for therapeutic intervention in cancer.


Assuntos
Neoplasias da Mama/genética , Neoplasias do Colo/genética , Regulação Neoplásica da Expressão Gênica , Proteínas Nucleares/metabolismo , Neoplasias Ovarianas/genética , Transcrição Gênica , beta Catenina/genética , Transporte Ativo do Núcleo Celular , Sequência de Bases , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Núcleo Celular/metabolismo , Proliferação de Células , Neoplasias do Colo/patologia , Simulação por Computador , Proteínas de Ligação a DNA , Feminino , Humanos , Mutação , Proteínas Nucleares/química , Proteínas Nucleares/genética , Oncogenes/genética , Neoplasias Ovarianas/patologia , Domínios Proteicos , Proteínas de Ligação a RNA , Regulação para Cima , Via de Sinalização Wnt/genética , beta Catenina/metabolismo
3.
Diabetologia ; 56(3): 497-507, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23242133

RESUMO

AIMS/HYPOTHESIS: Following on from the emerging importance of the pancreas circadian clock on islet function and the development of type 2 diabetes in rodent models, we aimed to examine circadian gene expression in human islets. The oscillator properties were assessed in intact islets as well as in beta cells. METHODS: We established a system for long-term bioluminescence recording in cultured human islets, employing lentivector gene delivery of the core clock gene Bmal1 (also known as Arntl)-luciferase reporter. Beta cells were stably labelled using a rat insulin2 promoter fluorescent construct. Single-islet/cell oscillation profiles were measured by combined bioluminescence-fluorescence time-lapse microscopy. RESULTS: Human islets synchronised in vitro exhibited self-sustained circadian oscillations of Bmal1-luciferase expression at both the population and single-islet levels, with period lengths of 23.6 and 23.9 h, respectively. Endogenous BMAL1 and CRY1 transcript expression was circadian in synchronised islets over 48 h, and antiphasic to REV-ERBα (also known as NR1D1), PER1, PER2, PER3 and DBP transcript circadian profiles. HNF1A and PDX1 exhibited weak circadian oscillations, in phase with the REV-ERBα transcript. Dispersed islet cells were strongly oscillating as well, at population and single-cell levels. Importantly, beta and non-beta cells revealed oscillatory profiles that were well synchronised with each other. CONCLUSIONS/INTERPRETATION: We provide for the first time compelling evidence for high-amplitude cell-autonomous circadian oscillators displayed in human pancreatic islets and in dispersed human islet cells. Moreover, these clocks are synchronised between beta and non-beta cells in primary human islet cell cultures.


Assuntos
Fatores de Transcrição ARNTL/metabolismo , Ilhotas Pancreáticas/metabolismo , Animais , Relógios Circadianos/genética , Relógios Circadianos/fisiologia , Feminino , Humanos , Técnicas In Vitro , Ilhotas Pancreáticas/fisiologia , Masculino , Pessoa de Meia-Idade , Ratos , Temperatura
4.
Acta Crystallogr D Biol Crystallogr ; 54(Pt 3): 476-8, 1998 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-9761933

RESUMO

A recombinant human uroporphyrinogen decarboxylase (E.C. 4.1.1.37, UROD) has been expressed in Escherichia coli and purified to homogeneity. Crystals grew by the hanging-drop vapor-diffusion technique from a starting solution containing 1.5 mg ml-1 protein. The crystals belong to the trigonal space group P3121 or its enantiomer P3221 and diffract to 3 A resolution. The unit-cell parameters are a = b = 103.4, c = 75.7 A and gamma = 120 degrees. The asymmetric unit contains one molecule. Preliminary structural predictions suggest for the protein a TIM-barrel type tertiary structure.


Assuntos
Uroporfirinogênio Descarboxilase/química , Cristalização , Escherichia coli , Expressão Gênica , Humanos , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/química , Uroporfirinogênio Descarboxilase/biossíntese , Uroporfirinogênio Descarboxilase/genética , Uroporfirinogênio Descarboxilase/isolamento & purificação , Difração de Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...